Pfizer Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Pfizer vs Merck: Chasing High Yield vs Higher Returns
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
How to Recession-Proof Your Retirement Before the Second Half of 2026
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
Why Pfizer's Current Price May Be Too Cheap to Ignore
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
3 Dividend Stocks to Buy and Hold Forever
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?
Is Pfizer Stock a "Value Trap" or a Generational Opportunity?
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Why Wall Street Is Dead Wrong About This Popular Stock